Daily Stock Analysis, INDA, INCYTE CORP, priceseries

INCYTE CORP. Daily Stock Analysis
Stock Information
Open
32.94
Close
33.07
High
33.14
Low
32.91
Previous Close
32.79
Daily Price Gain
0.28
YTD High
36.13
YTD High Date
Jun 3, 2019
YTD Low
30.93
YTD Low Date
Aug 22, 2019
YTD Price Change
0.43
YTD Gain
1.31%
52 Week High
36.13
52 Week High Date
Jun 3, 2019
52 Week Low
28.46
52 Week Low Date
Oct 26, 2018
52 Week Price Change
2.23
52 Week Gain
7.23%
Company Information
Stock Symbol
INDA
Exchange
NASDAQ
Company URL
http://www.incyte.com
Company Phone
3024986700
CEO
Hervé Hoppenot
Headquarters
Delaware
Business Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE 19803
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000879169
About

Incyte Corp. is a biopharmaceutical company, which focuses on the discovery, development, development, formulation, manufacturing and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology. Its product, Jakafi, a JAK1 and JAK2 inhibitor, is currently approved in the U.S. for the treatment of intermediate or high-risk myelofibrosis and is in development as a potential treatment for other cancers. The companywas founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Description

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. The company's clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis. In addition, it is developing itacitinib that is in Phase I/II clinical trials in combination with osimertinib for non-small cell lung cancer (NSCLC); INCB52793, INCB54329 (BRD), INCB57643 (BRD), and INCB53914 (PIM), which are in Phase I/II trials for the treatment of advanced malignancies; INCB54828 (FGFR1/2/3) that is in Phase II clinical trial the treatment of bladder cancer, cholangiocarcinoma, and 8p11 MPNs; INCB59872 (LSD1), which is in Phase II clinical trial the treatment of acute myeloid leukemia and small cell lung cancer; and capmatinib that is in Phase II clinical trial for the treatment of NSCLC and liver cancer. Further, the company's clinical stage products include epacadostat, which is in Phase II clinical trial for the treatment of various tumors, and in Phase I/II clinical trials for the treatment of NSCLC and bladder cancer, as well as in Phase III clinical trial for the treatment of advanced melanoma; and INCB01158, INCSHR1210, INCAGN1876 (GITR), and INCAGN1949 (OX40), which are in Phase I/II clinical trials for the treatment of solid tumors. It markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. The company has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer Inc; and Abramson Cancer Center. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.